Craig Hopkinson, M.D.
Executive Vice President, Research & Development and Chief Medical Officer

Craig Hopkinson, M.D., serves as Alkermes' Executive Vice President of Research & Development and Chief Medical Officer. In this role, Dr. Hopkinson leads the company's Discovery, Pharmaceutical Development, Early Stage Clinical Development, Late Stage Clinical Development, Regulatory Affairs, Clinical Operations, Project Management Office and Medical Affairs functions. He is responsible for the strategic development and execution of clinical development programs for the company's pipeline of drug candidates.

Dr. Hopkinson has nearly 30 years of experience building and leading clinical development organizations and medical affairs groups. He has led multidisciplinary development teams in a range of therapeutic areas, including neuroscience, oncology, gastroenterology, infectious diseases, cardiovascular conditions, inflammation, genetic diseases, hematology and neurodegenerative diseases. Before joining Alkermes in 2017, Dr. Hopkinson served as Senior Vice President of Medicines Development and Head of Global Medical Affairs at Vertex Pharmaceuticals. Prior to this role, Dr. Hopkinson held various leadership positions at Eisai Pharmaceuticals, Elan Pharmaceuticals, Actelion Pharmaceuticals and Pfizer. He previously served on the Board of Directors of Albireo Pharma, before its acquisition by Ipsen.

Dr. Hopkinson earned a Bachelor of Medicine and Bachelor of Surgery at the University of the Orange Free State in South Africa.

Brian Raymer, Ph.D.
Executive Director, Project Leadership & Strategy, Research

Brian Raymer, Ph.D. is a scientist and leader with more than 20 years of drug discovery and development experience. He joined Alkermes in 2018 and is currently the Executive Director of Project Leadership and Strategy, where he is responsible for advancing drug discovery projects across neuroscience and oncology. Prior to joining Alkermes, Dr. Raymer held roles of increasing scientific leadership responsibility at Pfizer and Novartis, focused primarily in the areas of cardiovascular, metabolic and CNS diseases. He has co-authored more than 20 peer-reviewed publications and abstracts, and is a co-inventor on 6 patents. Dr. Raymer holds a B.A. in Chemistry from Saint Olaf College and a Ph.D. in Organic Chemistry from Harvard University.

Julie Lekstrom Himes, M.D.
Senior Vice President, Clinical Development

Julie Lekstrom Himes, M.D. serves as Alkermes' Senior Vice President of Clinical Development. In this role, Dr. Himes leads the clinical operations, clinical research, biostatistics and drug safety & pharmacovigilance functions. She is responsible for overseeing the execution and development of all programs supporting clinical development.

Dr. Himes has more than 25 years of global clinical research and development experience in clinical stage programs across a variety of therapeutic areas. Prior to joining Alkermes, she served as Vice President and Head, Clinical Sciences, Rare Genetics and Hematology at Takeda Pharmaceutical

Company. Earlier in her career, Dr. Himes held various leadership positions at Vertex Pharmaceuticals, TARIS Biomedical, Coley Pharmaceutical Group, and Millennium Pharmaceuticals. In addition to her experience in the pharmaceutical industry, Dr. Himes has a background in academic research.

Dr. Himes received her bachelor's degree in Chemistry from the University of Virginia and her Doctor of Medicine from the Medical College of Virginia.

Charles Pak, Ph.D.
Vice President, New Product Planning

Charles Pak is Vice President of New Product Planning at Alkermes with responsibility across the neuroscience portfolio. He has extensive new product planning experience at various companies, including Syros Pharmaceuticals, Immunogen, Eisai, and Vertex Pharmaceuticals. He also has in-line marketing and launch experience with Bristol Myers Squibb in the U.S., UK, and Europe. Dr. Pak has a Ph.D. from the University of Texas MD Anderson Cancer Center and a MBA from The Wharton School, University of Pennsylvania.

Bhaskar Rege, Ph.D.
Senior Vice President, Pharmaceutical and Early Stage Development

Bhaskar Rege, Ph.D. serves as Alkermes' Senior Vice President of Pharmaceutical and Early Stage Development. In this role, Dr. Rege leads the DMPK, Clinical Pharmacology, Bioanalytical Sciences, Translational Medicine, Non-Clinical Safety Evaluation and Pharmaceutical Development functions.

Dr. Rege has over 20 years of pharmaceutical experience in multiple therapeutic areas and has led over 30 clinical trials. Before joining Alkermes as Global Development Lead in 2017, Dr. Rege held several roles at Eisai Pharmaceuticals, including serving as the Global Head of Clinical Pharmacology and Translation Medicine. Prior to this role, he held various positions in clinical pharmacology at Bristol Myers Squibb and Seattle Genetics.

Dr. Rege earned a Ph.D. in Pharmaceutical Sciences from Virginia Commonwealth University and Bachelor of Pharmacy in Pharmaceutical Sciences from The Bombay College of Pharmacy.

Julie Brooks, Ph.D.
Principal Scientist, Research

Julie Brooks is Principal Scientist of Research at Alkermes. She has extensive experience in neuroscience drug discovery focused on developing novel therapeutics for central nervous system disorders. Julie joined Alkermes in 2020 from Pfizer where she was part of the neuroscience research unit. She has contributed to many scientific publications including most recently related to the study of orexin in narcolepsy. Dr. Brooks earned a Ph.D. in Psychology, a master's degree in Psychology, and a Bachelor's degree in Psychology from The Ohio State University.

Richard Pops
Chairman and Chief Executive Officer

Richard Pops serves as Alkermes' Chairman and Chief Executive Officer. He joined Alkermes as CEO in 1991 and under his leadership, the organization has grown from a privately held company with 25 employees to an international, publicly-traded biopharmaceutical company with multiple FDA-approved proprietary products.

Mr. Pops currently serves on the Boards of Directors of Neurocrine Biosciences, the Biotechnology Industry Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA), and has previously served on the Boards of Directors of Acceleron Pharma, Inc. and Epizyme, Inc.

As a Co-Chair of BIO's Regulatory Environment Committee, and a member of its Health Section Governing Board, and as a member of PhRMA's FDA and Biomedical Research Committee, Mr. Pops is an influential industry leader on FDA regulatory policy issues, including recent Prescription Drug User Fee Act reauthorizations. Mr. Pops has also played an industry leadership role in identifying pathways to allow patient voices to be incorporated into the drug development and approval process, which is a fundamental principle on which Alkermes operates.